Effect of hr-IL2 treatment on intestinal P-glycoprotein expression and activity in Caco-2 cells

被引:18
作者
Belliard, AM
Tardivel, S
Farinotti, R
Lacour, B [1 ]
Leroy, C
机构
[1] Fac Pharm Chatenay Malabry, Lab Physiol Pharm Clin, UPRES 2706, F-92296 Chatenay Malabry, France
[2] Fac Pharm Chatenay Malabry, EPHE Physiol, Lab Metab Mineral Mammiferes, F-92296 Chatenay Malabry, France
关键词
D O I
10.1211/002235702320266262
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Caco-2 cells were used to investigate the effect of human recombinant interleukin-2 (IL-2) on intestinal P-glycoprotein (P-gp) transporter activity in-vitro. More specifically the efflux function of P-gp was studied by measuring the transepithelial transport of rhodamine-123, a fluorescent substrate of P-gp. Its transport was completely inhibited by two specific P-gp inhibitors, ciclosporin A and GG918, in our experiments. Conversely, these two specific P-gp inhibitors inhibited only 50% of transepithelial transport when [H-3]vincristine was used as substrate. After Caco-2 cells were treated with 100 IU mL(-1) (6.1 ng mL(-1)) IL2 for 24 h, a significant diminution (21%) of P-gp transporter function was observed with rhodamine-123 substrate. This effect was also confirmed after 48 and 72 h of exposure to IL2. However, for higher concentrations of IL2 (1000 and 5000 IU mL(-1)), diminution of P-gp function only occurred after a longer treatment period (48 h and more). The inhibitory effect of IL2 on P-gp activity was found to be independent of tight junction function as demonstrated by constant transepithelial electrical resistance (TEER) measurements for all experimental conditions encountered in this study (time and concentration of IL2 exposure). Furthermore, the MDR1 mRNA level was found to be strongly repressed in Caco-2 cells exposed with 1000 IU mL-1 IL2 for 72 h while the amount of MRP1 mRNA remained unchanged. In conclusion, acute incubation of Caco-2 cells with IL2 induced a decrease of P-gp transporter expression and activity.
引用
收藏
页码:1103 / 1109
页数:7
相关论文
共 33 条
[1]   Cytokine mRNA expression in intestinal tissue of interleukin-2 deficient mice with bowel inflammation [J].
Autenrieth, IB ;
Bucheler, N ;
Bohn, E ;
Heinze, G ;
Horak, I .
GUT, 1997, 41 (06) :793-800
[2]   EFFECT OF TURPENTINE-INDUCED INFLAMMATION ON THE DISPOSITION KINETICS OF PROPRANOLOL, METOPROLOL, AND ANTIPYRINE IN THE RAT [J].
BELPAIRE, FM ;
DESMET, F ;
CHINDAVIJAK, B ;
FRAEYMAN, N ;
BOGAERT, MG .
FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1989, 3 (02) :79-88
[3]  
Bertilsson PM, 2001, J PHARM SCI, V90, P638, DOI 10.1002/1520-6017(200105)90:5<638::AID-JPS1020>3.0.CO
[4]  
2-L
[5]   Recombinant interleukin-2 treatment decreases P-glycoprotein activity and paclitaxel metabolism in mice [J].
Bonhomme-Faivre, L ;
Pelloquin, A ;
Tardivel, S ;
Urien, S ;
Mathieu, MC ;
Castagne, V ;
Lacour, B ;
Farinotti, R .
ANTI-CANCER DRUGS, 2002, 13 (01) :51-57
[6]   MECHANISMS OF INTERLEUKIN-2-INDUCED DEPRESSION OF HEPATIC CYTOCHROME-P-450 IN MICE [J].
CANTONI, L ;
CARELLI, M ;
GHEZZI, P ;
DELGADO, R ;
FAGGIONI, R ;
RIZZARDINI, M .
EUROPEAN JOURNAL OF PHARMACOLOGY-ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY SECTION, 1995, 292 (3-4) :257-263
[7]   FUNCTIONAL INTERLEUKIN-2 RECEPTORS ON INTESTINAL EPITHELIAL-CELLS [J].
CIACCI, C ;
MAHIDA, YR ;
DIGNASS, A ;
KOIZUMI, M ;
PODOLSKY, DK .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (01) :527-532
[8]   Rapid effect of interleukin-2 therapy in human immunodeficiency virus-infected patients whose CD4 cell counts increase only slightly in response to combined antiretroviral treatment [J].
David, D ;
Naït-Ighil, L ;
Dupont, B ;
Maral, J ;
Gachot, B ;
Thèze, J .
JOURNAL OF INFECTIOUS DISEASES, 2001, 183 (05) :730-735
[9]   Interleukin 2 modulates intestinal epithelial cell function in vitro [J].
Dignass, AU ;
Podolsky, DK .
EXPERIMENTAL CELL RESEARCH, 1996, 225 (02) :422-429
[10]   Decrease in hepatic cytochrome P450 after interleukin-2 Immunotherapy [J].
Elkahwaji, J ;
Robin, MA ;
Berson, A ;
Tinel, M ;
Lettéron, P ;
Labbe, G ;
Beaune, P ;
Elias, D ;
Rougier, P ;
Escudier, B ;
Duvillard, P ;
Pessayre, D .
BIOCHEMICAL PHARMACOLOGY, 1999, 57 (08) :951-954